Source comparison
Addiction Recovery Peptides 2026 Update: Research Comparison
BPC-157 Blood-brain barrier repair, VEGF upregulation, tight junction stabilization Acute withdrawal (days 1–14) 250–500 mcg SC twice daily for 2–8 weeks Preclinical only. No Phase III RCTs Strongest mechanistic rationale for acute symptom reduction; lacks hum
This comparison does not assign a generated winner or score.
- BPC-157
- Blood-brain barrier repair, VEGF upregulation, tight junction stabilization
- Acute withdrawal (days 1–14)
- 250–500 mcg SC twice daily for 2–8 weeks
- Preclinical only. No Phase III RCTs
- Strongest mechanistic rationale for acute symptom reduction; lacks human efficacy data
- Selank
- GABA-A receptor modulation, BDNF elevation, cortisol reduction
- Acute through PAWS (days 1–90)
- 300–600 mcg intranasal daily for 3–6 weeks
- Small human studies, no RCTs
- Effective anxiolytic without dependence risk; replication needed
- Thymalin
- Thymic peptide restoration, IL-6/TNF-alpha suppression, immune recovery
- Post-acute (weeks 3+)
- 5–10 mg IM twice weekly for 4–10 weeks
- Observational studies, Eastern European trials
- Targets systemic inflammation overlooked in Western protocols
- Dihexa
- HGF/c-Met pathway activation, synaptogenesis, dendritic spine density
- Post-acute cognitive repair (weeks 4+)
- 1–5 mg SC daily for 4–8 weeks
- Animal models only
- Most potent neuroplasticity compound in preclinical testing; no human safety data